Continuous infusion of recombinant activated factor VII during caesarean section delivery in a patient with congenital factor VII deficiency

Haemophilia. 2000 Sep;6(5):588-90. doi: 10.1046/j.1365-2516.2000.00424.x.

Abstract

Recombinant activated factor VII (rFVIIa) can be used as an alternative therapy in patients with FVII deficiency. However, as the drug has a very short half-life, continuous infusion could be a meaningful administration modality. We report the case of a 30-year-old woman with moderate FVII deficiency and human immunodeficiency virus infection who underwent a caesarean section delivery. She was treated with a continuous infusion of rFVIIa and did not suffer any bleeding complication. The continuous infusion of rFVIIa was a safe and effective therapeutic approach for our patient, maintaining her levels of FVII:C and avoiding bleeding during caesarean section and afterwards.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Blood Loss, Surgical / prevention & control
  • Cesarean Section / adverse effects
  • Cesarean Section / methods*
  • Factor VII / administration & dosage*
  • Factor VII Deficiency / complications*
  • Factor VII Deficiency / congenital*
  • Factor VII Deficiency / drug therapy*
  • Female
  • HIV Infections
  • Hemorrhage / drug therapy
  • Hemorrhage / prevention & control
  • Humans
  • Infusions, Parenteral
  • Pregnancy
  • Pregnancy Complications, Hematologic / drug therapy
  • Recombinant Proteins / administration & dosage

Substances

  • Recombinant Proteins
  • Factor VII